Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more

Partial nephrectomy versus radical nephrectomy for low risk kidney cancer

This study looked at the survival of patients following partial nephrectomy versus radical nephrectomy for low-risk renal cell carcinoma (RCC). A total of 1995 patients were included in the study and 53% had partial nephrectomy. The size of the tumour, the grade of the tumour (how aggressive it was), the number of blood vessels supplying […]

read more

Stereotactic radiotherapy for metastatic kidney cancer patients on TKIs

This phase 2 study looked at the use of stereotactic radiotherapy to treat metastatic renal cell carcinoma (RCC) in patients where the cancer had spread and there were a small number of metastases. These patients were on a tyrosine kinase inhibitor as the first or second medicine for their cancer. The aim of the study […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer

Non-clear cell RCC is about 20-25% of all RCC diagnoses and usually has worse survival outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have been shown to help patients with non-clear cell RCC. KEYNOTE-427 is a phase 2 study that looked at the treatment of people with RCC with pembrolizumab as their […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer

KEYNOTE-427 is an open-label, single-arm, phase II study to look at the effectiveness of pembrolizumab as a first-line treatment for people with advanced clear cell RCC. At ESMO this year, updated efficacy, and safety results after a minimum follow-up of 41 months were presented. This study looked at the treatment of people with RCC with […]

read more

ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

The use of two medicines together (combination therapies) for previously untreated patients with RCC that has spread (metastatic RCC) is fast becoming standard treatment for these patients. A study called CheckMate-214 showed that a combination of the immune checkpoint inhibitors nivolumab plus ipilimumab helped patients with intermediate or high risk RCC live longer than those […]

read more

55,000 cancer patients miss treatment target over 6 years

Cancer Research UK has reported that over the past 6 years, almost 55,000 cancer patients have missed the 62-day wait for treatment. The key reasons for this are shortages in workforce and diagnostic equipment. These patients should have been diagnosed quicker and started treatment sooner. However, the government’s own target of 85% of cancer patients […]

read more

ESMO 2021: Pembrolizumab as adjuvant therapy

Adjuvant therapy is medication that is given in addition to surgery to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma; however, the cancer can […]

read more

ESMO 2021: COVID-19 vaccine in cancer patients is comparable to the general population

The latest findings from five studies presented at the ESMO Congress 2021 help cut short the debate on the safety and efficacy of COVID vaccines in cancer patients and re-affirm ESMO’s recommendations for early vaccination of this high-priority population, as outlined in the ESMO ten statements, which were updated in April 2021. Patients with cancer or a history […]

read more

ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in several changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. This […]

read more
Showing 1 to 10 of 1063 results
  TOP